Overview

A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough

Status:
NOT_YET_RECRUITING

Trial end date:
2029-07-01

Target enrollment:

Participant gender:

Summary

The FORTITUDE trial will provide head-to-head evidence on the benefits and harms of two commonly prescribed neuromodulators (low-dose morphine and pregabalin), the effectiveness of a virtual cough control therapy, exploratory assessment of potential synergy in combining these interventions, and the long-term outcomes of these treatments in patients with refractory or unexplained chronic cough.

Phase:

PHASE4

Details

Lead Sponsor:

McMaster University

Treatments:

Morphine
Pregabalin